UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005032
Receipt number R000005987
Scientific Title Investigation of biomarkers for predicting effectiveness of treatments for inflammatory bowel diseases
Date of disclosure of the study information 2011/03/01
Last modified on 2020/03/21 00:26:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of biomarkers for predicting effectiveness of treatments for inflammatory bowel diseases

Acronym

Investigation of biomarkers for predicting effectiveness of treatments for inflammatory bowel diseases

Scientific Title

Investigation of biomarkers for predicting effectiveness of treatments for inflammatory bowel diseases

Scientific Title:Acronym

Investigation of biomarkers for predicting effectiveness of treatments for inflammatory bowel diseases

Region

Japan


Condition

Condition

inflammatory bowel diseases

Classification by specialty

Medicine in general Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate biomarkers for predicting effectiveness of leukocyteapheresis, anti-TNF alpha antibody and tacrolimus for inflammatory bowel diseases

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To investigate the several inflammatory substances to find out the usefullness biomarkers to predict the efficacy and prognosis of treatments in inflammatory bowel diseases

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Other

Interventions/Control_1

to measure several inflammatory substances before and after the leukocyteapheresis, anti-TNF alpha antibody and tacrolimus for patients with inflammatory bowel diseases

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who are applicable for the treatments of leukocyteapheresis, anti-TNF alpha antibody and tacrolimus
Patients who argee informed consent

Key exclusion criteria

Patients who are not applicable for the treatments of leukocyteapheresis, anti-TNF alpha antibody and tacrolimus
Patients who disargee informed consent

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Shingo
Middle name
Last name Kato

Organization

Saitama medical Center, Saitama medical University

Division name

Department of Gastroenterology and Hepatology

Zip code

350-8550

Address

1981 Kamoda, Kawagoe City, Saitama, Japan

TEL

049-228-3564

Email

skato@saitama-med.ac.jp


Public contact

Name of contact person

1st name Shingo
Middle name
Last name Kato

Organization

Saitama medical Center, Saitama medical University

Division name

Department of Gastroenterology and Hepatology

Zip code

350-8550

Address

1981 Kamoda, Kawagoe City, Saitama, Japan

TEL

049-228-3564

Homepage URL


Email

skato@saitama-med.ac.jp


Sponsor or person

Institute

Saitama medical Center, Saitama medical University

Institute

Department

Personal name



Funding Source

Organization

Saitama medical Center, Saitama medical University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Saitama Medical Center

Address

1981 Kamoda, Kawagoe City, Saitama 3508550, Japan

Tel

049-228-3902

Email

smcrinri@saitama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 03 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2011 Year 03 Month 01 Day

Date of IRB

2011 Year 03 Month 01 Day

Anticipated trial start date

2011 Year 03 Month 01 Day

Last follow-up date

2018 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 02 Month 05 Day

Last modified on

2020 Year 03 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005987


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name